论文部分内容阅读
1977年 Grüntzig(瑞士)首先用经皮冠脉腔内成形术(PTCA)治疗冠心病成功并迅速推广,目前美国已将 PTCA 作为冠心病的主要疗法.作者在美国 Cleveland Clinic 观察了237例 PTCA,除2例未能成功.需行搭桥术(CABG)外,其余均显示良好疗效.其中施术时间最短的1例,由股动脉穿刺至全部手术完毕只21分钟,故 PTCA 具有广阔前景.腔内成形术的原理冠状动脉狭窄及阻塞性病变的病理基础是粥样斑块形成或(和)血栓性物质阻塞管腔所引起,阻塞物的主要结构成分为水、胆固醇类晶体以及疏松的结缔组织.实验表明,这类物质可被加压球囊压缩至血管壁周围或沿管壁延伸,组织学检查可见
In 1977, Grüntzig (Switzerland) firstly successfully and rapidly promoted the treatment of coronary heart disease by percutaneous transluminal coronary angioplasty (PTCA), and nowadays the United States has taken PTCA as the main therapy for coronary heart disease.According to the American Cleveland Clinic, 237 PTCA, Except CABG, the others showed good curative effect.While the shortest operative time was 1, puncture from the femoral artery to the complete operation was only 21 minutes, so PTCA has a broad prospect. The principle of endoplasty The pathological basis of coronary artery stenosis and obstructive lesions is caused by the formation of atherosclerotic plaques or the clogging of the lumen by thrombotic substances. The main structural components of the obstruction are water, cholesterol crystals and loose connective tissue Organization.Experiments have shown that such substances can be compressed balloon compression to the vascular wall around or along the wall extension, histological examination can be seen